» Articles » PMID: 28123170

Clinicopathological Features and Prognosis of Intrahepatic Cholangiocarcinoma After Liver Transplantation and Resection

Overview
Journal Ann Transplant
Specialty General Surgery
Date 2017 Jan 27
PMID 28123170
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND Intrahepatic cholangiocarcinoma (ICC) can be incidentally diagnosed after liver transplantation (LT). We investigated the clinicopathological features of LT recipients with ICC and compared prognosis with that of the control group. MATERIAL AND METHODS We identified 16 recipients with ICC in our institutional database. The propensity score-matched control group comprised 100 ICC patients who underwent hepatic resection (HR). RESULTS ICC incidence was 0.5% in all adult LT patients and 1.2% in adult recipients with primary liver cancer. Mean age was 58.0±4.8 years and 15 were male. All ICCs were diagnosed incidentally in the explanted livers. Mean ICC tumor diameter was 2.5±1.1 cm and 14 recipients had a single tumor. Tumor stages were I in 9, II in 5, and IV in 2. Concurrent second primary liver cancer was detected as hepatocellular carcinoma in 7 and combined hepatocellular carcinoma-cholangiocarcinoma in 1. Tumor recurrence and patient survival rates were 56.2% and 81.3% at 1 year and 78.1% and 52.4% at 5 years, respectively. Presence of second cancer did not affect tumor recurrence (p=0.959) or patient survival (p=0.737). All 3 patients with very early ICC did not show ICC recurrence. Compared with the control group, the tumor recurrence rate was higher after LT (p=0.024), but this difference disappeared after analysis was confined to recipients with ICC alone (p=0.121). Post-recurrence survival was not different after HR and LT (p=0.082). CONCLUSIONS ICC is rarely diagnosed after LT and half of such patients have second liver cancer. Post-transplant prognosis of ICC is poor except for very early ICC; thus, strict surveillance is mandatory.

Citing Articles

British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.

Rushbrook S, Kendall T, Zen Y, Albazaz R, Manoharan P, Pereira S Gut. 2023; 73(1):16-46.

PMID: 37770126 PMC: 10715509. DOI: 10.1136/gutjnl-2023-330029.


Cholangiocarcinoma - novel biological insights and therapeutic strategies.

Ilyas S, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang J Nat Rev Clin Oncol. 2023; 20(7):470-486.

PMID: 37188899 PMC: 10601496. DOI: 10.1038/s41571-023-00770-1.


Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma.

Rauchfuss F, Ali-Deeb A, Rohland O, Dondorf F, Ardelt M, Settmacher U Curr Oncol. 2022; 29(3):1932-1938.

PMID: 35323357 PMC: 8947647. DOI: 10.3390/curroncol29030157.


Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.

Park G, Hwang S, Ahn C, Kim K, Moon D, Ha T J Korean Med Sci. 2020; 35(11):e69.

PMID: 32193900 PMC: 7086089. DOI: 10.3346/jkms.2020.35.e69.


Impact of tumor size and cirrhotic background for differentiating HCC and ICC with CEUS: does it matter for patients undergoing hepatectomy?.

Jin C, Zhang X, Li J, Li C, Peng W, Wen T Oncotarget. 2017; 8(48):83698-83711.

PMID: 29137375 PMC: 5663547. DOI: 10.18632/oncotarget.19624.